ArticleAlzheimer's research & therapy2021
Recruitment and retention of participant and study partner dyads in two multinational Alzheimer's disease registration trials.
Article in Alzheimer's research & therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.
- The Challenges of Enrollment and Retention: A Systematic Review of Psychosocial Behavioral Interventions for Patients With Cancer and Their Family Caregivers.Journal of pain and symptom management · 2021Pooled it
- Evaluating In-home Assistive Technology for Dementia Caregivers.Clinical gerontologistTrial
- Reflecting upon Session 8 of the 2023 dementia care summit: Diversity beyond outreach, recruitment, and retention.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Promising Natural Remedies for Alzheimer's Disease Therapy.Molecules (Basel, Switzerland) · 2025Review
- Perceptions about dementia clinical trials among underrepresented populations: a nationally representative survey of U.S. dementia caregivers.Alzheimer's research & therapy · 2024Article
- Article
- Perceptions about dementia clinical trials among underrepresented populations: A nationally representative survey of U.S. dementia caregivers.Research square · 2024Article
- Estimating attrition in mild-to-moderate Alzheimer's disease and mild cognitive impairment clinical trials.Alzheimer's research & therapy · 2023Article
- The Role ofJournal of transcultural nursing : official journal of the Transcultural Nursing Society · 2023Article
- Retention of Study Partners in Longitudinal Studies of Alzheimer Disease.Journal of Alzheimer's disease : JAD · 2023Article
- Retaining Participants in Longitudinal Studies of Alzheimer's Disease.Journal of Alzheimer's disease : JAD · 2022Article
- A geroscience motivated approach to treat Alzheimer's disease: Senolytics move to clinical trials.Mechanisms of ageing and development · 2021Review
- Impact of study partner replacement in a mild cognitive impairment clinical trial.Alzheimer's & dementia (New York, N. Y.)Article
- Quantifying Recruitment Source and Participant Communication Preferences for Alzheimer's Disease Prevention Research.The journal of prevention of Alzheimer's diseaseArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
backgroundEarly study exit is detrimental to statistical power and increases the risk for bias in Alzheimer's disease clinical trials. Previous analyses in early phase academic trials demonstrated associations between rates of trial incompletion and participants' study partner type, with participants enrolling with non-spouse study partners being at greater risk.
methodsWe conducted secondary analyses of two multinational phase III trials of semagacestat, an oral gamma secretase inhibitor, for mild-to-moderate AD dementia. Cox's proportional hazards regression model was used to estimate the relationship between study partner type and the risk of early exit from the trial after adjustment for a priori identified potential confounding factors. Additionally, we used a random forest model to identify top predictors of dropout.
resultsAmong participants with spousal, adult child, and other study partners, respectively, 35%, 38%, and 36% dropped out or died prior to protocol-defined study completion, respectively. In unadjusted models, the risk of trial incompletion differed by study partner type (unadjusted p value = 0.027 for test of differences by partner type), but in models adjusting for potential confounding factors, the differences were not statistically significant (p value = 0.928). In exploratory modeling, participant age was identified as the primary characteristic to explain the relationship between study partner type and the risk of failing to complete the trial. Participant age was also the strongest predictor of trial incompletion in the random forest model.
conclusionsAfter adjustment for age, no differences in the risk of incompletion were observed when comparing participants with different study partner types in these trials. Differences between our findings and the findings of previous studies may be explained by differences in trial phase, size, geographic regions, or the composition of academic and non-academic sites.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.